无事件生存期作为前列腺癌复合终点不能替代总生存期
该研究基于ICECaP数据库15项放疗试验的10350例局限期前列腺癌患者数据,评估以PSA为基础的无事件生存期(EFS)对总生存期(OS)的替代性。患者水平EFS与OS相关性为0.43(95%CI 0.42-0.44),试验水平R²为0.35(95%CI 0.01-0.60),低于预设的R²≥0.7阈值,表明EFS是OS的弱替代终点,不适合作为加速III期(新)辅助放疗试验的中间终点。
要点
- EFS与OS患者水平相关性仅0.43,试验水平R²为0.35,均未达替代阈值。
- EFS不适合替代OS用于加速前列腺癌放疗为基础的III期试验。
- 研究纳入15项放疗试验共10350例,中位随访10年。
核心结论
- EFS是OS的弱替代终点,不适用于替代OS加速以放疗为基础的III期(新)辅助前列腺癌治疗试验。
研究设计与样本
- 基于ICECaP数据库的个体患者数据荟萃分析,纳入1987至2011年入组的15项放疗试验共10350例患者,中位随访10年。
- 采用两阶段荟萃验证模型评估EFS对OS的替代性,患者水平用Copula模型Kendall's tau相关,试验水平用加权线性回归log(HR)-OS对log(HR)-EFS的R²。
- 预设临床相关替代阈值R²≥0.7。
主要发现
- 患者水平EFS与OS相关性为0.43(95%CI 0.42-0.44)。
- 试验水平R²为0.35(95%CI 0.01-0.60),低于预设的R²≥0.7阈值。
关键数值与推荐
- EFS定义为随机分组至首次疾病复发证据(包括生化失败、局部或区域复发、远处转移或任何原因死亡)或末次PSA评估删失的时间。
- 临床相关替代预先定义为R²≥0.7。
临床怎么用
- 在局限期前列腺癌放疗为基础的III期(新)辅助试验中,不应使用EFS作为OS的替代终点来加速试验评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recently, we have shown that metastasis-free survival is a strong surrogate for overall survival (OS) in men with intermediate- and high-risk localized prostate cancer and can accelerate the evaluation of new (neo)adjuvant therapies. Event-free survival (EFS), an earlier prostate-specific antigen (PSA)-based composite end point, may further expedite trial completion. METHODS: EFS was defined as the time from random assignment to the date of first evidence of disease recurrence, including biochemical failure, local or regional recurrence, distant metastasis, or death from any cause, or was censored at the date of last PSA assessment. Individual patient data from trials within the Intermediate Clinical Endpoints in Cancer of the Prostate-ICECaP-database with evaluable PSA and disease follow-up data were analyzed. We evaluated the surrogacy of EFS for OS using a 2-stage meta-analytic validation model by determining the correlation of EFS with OS (patient level) and the correlation of treatment effects (hazard ratios [HRs]) on both EFS and OS (trial level). A clinically relevant surrogacy was defined a priori as an R2 ≥ 0.7. RESULTS: Data for 10,350 patients were analyzed from 15 radiation therapy-based trials enrolled from 1987 to 2011 with a median follow-up of 10 years. At the patient level, the correlation of EFS with OS was 0.43 (95% CI, 0.42 to 0.44) as measured by Kendall's tau from a copula model. At the trial level, the R2 was 0.35 (95% CI, 0.01 to 0.60) from the weighted linear regression of log(HR)-OS on log(HR)-EFS. CONCLUSION: EFS is a weak surrogate for OS and is not suitable for use as an intermediate clinical end point to substitute for OS to accelerate phase III (neo)adjuvant trials of prostate cancer therapies for primary radiation therapy-based trials.
引用
- Xie W, Regan MM, Buyse M, et al. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020. PMID: 32552276. doi:10.1200/JCO.19.03114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。